Derivation Web

source_6932bf447dd04294

by researka:v2 · 2026-05-27 23:43:54.922614+04:00

# Alpha memo — telomere

**Headline:** Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects
**Confidence:** `evidence_backed_signal`
**Memo surface:** `alpha memo`
**Snapshot:** `2026-05-27T19-41-35Z`
**Run:** `telomere-evidence-2026-05-27T19-41-35Z`
**Direct source breadth:** `5` direct cited source(s)
**Source breadth:** `5/5` unique cited source(s)

## One-sentence thesis

The cited A/B receipts support a specific working claim: Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98); but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The evidence exposes a paradoxical role of telomere length—cardioprotective yet carcinogenic—modulated by methodological heterogeneity and genetic background, suggesting that risk assessment must account for measurement techniques and disease-specific contexts.

Known / obvious (do not republish): Telomere length shortens with chronological age; Shorter telomeres are associated with increased all-cause mortality risk

Real tension: Fact 109012 (lower CHD risk with longer TL) vs Fact 109013 (higher cancer risk with longer TL) in the same UK Biobank population aged 60+

## Evidence receipts

- `fact_id=109012` (`A_core`) — Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) doi=10.1111/acel.13017
- `fact_id=109013` (`A_core`) — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16) doi=10.1111/acel.13017
- `fact_id=3475` (`A_core`) — In the comparison of the longest versus shortest third of TL, we observed a marginally positive association between longer TL and higher risk of total cancers [OR = 1.086; 95% CI, 0.952-1.238]. doi=10.1158/1055-9965.epi-16-0968
- `fact_id=172806` (`A_core`) — Variant status was significantly associated with transplant-free survival (discovery: age-, sex-, and ancestry-adjusted hazard ratio, 3.73) doi=10.1164/rccm.201902-0360oc
- `fact_id=145145` (`A_core`) — one SD TL decrement-associated hazard ratio of 1.09 (95% CI: 1.06-1.13) doi=10.1016/j.arr.2018.09.002
- `fact_id=172432` (`A_core`) — longer LTL was associated with higher brain volume (β = 0.43, 95%CI: 0.36-0.50%, p = 0.008, N = 1102) doi=10.1016/j.arr.2022.101679

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

## Provenance / priority

- **Topic:** `telomere`
- **Author:** Dom Lynch
- **ORCID:** _not configured_
- **Version:** 1.0
- **License:** CC BY-NC 4.0
- **Canonical URL:** _not assigned_
- **Suggested citation:** Dom Lynch. (2026). Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects. ReseaRka Evidence Index. Version 1.0.
- **Run bundle SHA-256:** `f87d32bf6f8024c7c1786fe09d30916f479b7ad4aca236ffc5ac42b88539b95c`
- **Memo SHA-256:** `f1f71321d545b30354457fc320f7134991a8f498ff2c6db93ce7f3bed6b1e00e`
- **Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "e9021495-292a-4d07-9c1c-cb8bf16a2c3c",
  "title": "Cardiovascular protection versus cancer risk: a Mendelian randomization and meta-analysis synthesis of telomere length effects"
}